EU/3/10/732

Table of contents

About

On 10 June 2010, orphan designation (EU/3/10/732) was granted by the European Commission to Nexus Oncology Ltd, United Kingdom, for entinostat for the treatment of Hodgkin's lymphoma.

In February 2013, Nexus Oncology Ltd changed name to Ockham Europe Limited.

The sponsorship was transferred to Syndax Limited, United Kingdom, in April 2015.

The sponsorship was transferred to Southwood Research Limited The Netherlands, in February 2019.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Entinostat
Disease / condition
Treatment of Hodgkin's lymphoma
Date of decision
10/06/2010
Outcome
Positive
Orphan decision number
EU/3/10/732

Sponsor's contact details

Southwood Research Limited
Gustav Mahlerplein 2
1082 MA Amsterdam
The Netherlands
Tel. + 31 20 799 7405
E-mail:  tom@southwoodresearch.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating